General Updates

September 07, 2026 The Manager, Listing Department BSE Limited The National Stock Exchange of India Ltd. Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai - 400 051 Dalal Street, Mumbai - 400 001 NSE Symbol: PANACEABIO BSE Scrip Code: 531349 Sub.: Intimation of Book Closure for Annual General Meeting Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir / Madam, This is in continuation to our letter dated August 13, 2026, intimating that the 42nd Annual General Meeting (“AGM”) of the Company will be held on Tuesday, September 29, 2026, at 11:30 A.M. (IST) through Video Conferencing (“VC”) / Other Audio Visual Means (“OAVM”) in compliance with the applicable General Circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. We would like to inform you that the Register of Members and Share Transfer Books will remain closed from Friday, September 25, 2026, to Tuesday, September 29, 2026 (both days inclusive) for the purpose of Annual General Meeting. This is for your kind information and record please. Thanking you, Sincerely yours, For Panacea Biotec Limited Ankit Jain General Manager - Legal & Company Secretary Encl.: As Above Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd. Office : Ambala Chandigarh Highway, Lalru – 140501, Punjab Correspondence/Corporate office : B-1 Extn./A-27, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-4167 9070 Email: companysec@panaceabiotec.com Panacea Biotec Limited (CIN: L33117PB1984PLC022350) Regd. Office: Ambala - Chandigarh Highway, Lalru - 140501, Punjab, India Corp. Office: B-1 Extn./A-27, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi - 110044 Website: www.panaceabiotec.com, E-mail: companysec@panaceabiotec.com, Tel: +91 11 41679000 NOTICE NOTICE is hereby given that the 42nd Annual General Meeting (“AGM”) of the Members of Panacea Biotec Limited (“the Company”) will be held on Tuesday, September 29, 2026, at 11:30 A.M. through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”), to transact the following businesses: ORDINARY BUSINESS: 1. To consider and adopt (a) the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, together with the reports of the Board of Directors and the Auditors thereon; and (b) the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, including Auditors’ Report thereon and in this regard, if thought fit, to pass the following resolutions as Ordinary Resolutions: a) “RESOLVED THAT the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, together with the reports of the Board of Directors and the Auditors thereon, as circulated to the Members, be and are hereby considered and adopted.” b) “RESOLVED THAT the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, together with the Auditors’ Report thereon, as circulated to the Members, be and are hereby considered and adopted.” 2. To appoint a director in place of Mr. Ankesh Jain who retires by rotation and being eligible, offers himself for re-appointment and in this regard, if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013, Mr. Ankesh Jain (DIN: 03556647) who retires by rotation at this meeting and being eligible, offered himself for re-appointment, be and is hereby re-appointed as a director, liable to retire by rotation.” 3. To appoint a director in place of Mr. Harshet Jain who retires by rotation and being eligible, offers himself for re-appointment and in this regard, if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013, Mr. Harshet Jain (DIN: 08732974) who retires by rotation at this meeting and being eligible, offered himself for re-appointment, be and is hereby re-appointed as a director, liable to retire by rotation.” SPECIAL BUSINESS: 4. To consider appointment of Mr. Rajinder Singh Manku (DIN: 09706881) as an independent director of the Company and in this regard, if thought fit, to pass with or without modification(s), the following resolution, as a Special Resolution: “RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152, 161 and other applicable provisions of the Companies Act, 2013 (“the Act”) read with the Companies (Appointment and Qualification of Directors) Rules, 2014, Schedule IV to the Act and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) (including any statutory modification(s) or re-enactment(s) thereof for the time being in force) and the Articles of Association of the Company, Mr. Rajinder Singh Manku (DIN: 09706881), who was appointed by the Board of Directors, based on the recommendation of the Nomination and Remuneration Committee as an additional director (in the category of non-executive independent director) of the Company and who meets the applicable criteria for independence under the Act and the SEBI LODR Regulations and in respect of whom the Company has received a notice in writing from a Member under Section 160(1) of the Act, be and is hereby appointed as an independent director of the Company, not liable to retire by rotation, for a period of 5 (five) consecutive years with effect from July 01, 2026. RESOLVED FURTHER THAT the Board of Directors, the Company Secretary and the Chief Financial Officer of the Company be and are hereby severally authorised to do all such acts, matters, deeds and things and to sign all such documents, papers and writings as may be necessary or expedient to give effect to this resolution and for matters connected therewith or incidental thereto.” 5. To consider and ratify the remuneration of Cost Auditors and in this regard, if thought fit, to pass the following resolution as an Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 148 and other applicable provisions, if any, of the Companies Act, 2013 read with the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), the remuneration of ₹1,25,000/- (Rupees One Lakh Twenty Five Thousand Only) (including out of pocket expenses as may be incurred in connection with the audit but excluding out of pocket expenses as may be incurred in connection with the outstation travels as per actuals) and Goods and Service Tax or other Government levies as may be applicable, as approved by the Board of Directors to be paid to M/s Jain Sharma & Associates, Cost Accountants (Firm Registration Number: 000270), appointed as Cost Auditors of the Company, to conduct the audit of cost records of the Company for the financial year 2026-27, be and is hereby confirmed and ratified. Panacea Biotec Limited 1 RESOLVED FURTHER THAT the Board of Directors, the Company Secretary and the Chief Financial Officer of the Company be and are hereby severally authorised for and on behalf of the Company to do all such acts, matters, deeds and things and to sign all such documents, papers and writings as may be necessary, proper or expedient to give effect to this resolution.” By order of the Board For Panacea Biotec Limited Ankit Jain Place : New Delhi General Manager – Legal and Company Secretary Date : August 13, 2026 Membership No.: A29499 NOTES: 1. The Ministry of Corporate Affairs (“MCA”), Government of India, inter-alia vide its General Circular Nos. 14/2020, 17/2020, 20/2020, 09/2024 dated April 08, 2020, April 13, 2020, May 05, 2020 and September 19, 2024, re [Showing first 8,000 characters — download PDF for full document]